Air Street Press

Nathan Benaich (Air Street Capital)
undefined
Nov 4, 2025 • 3min

PARIMA’s first regulatory approval and another wake-up call for Europe

PARIMA, a global leader in cultivated proteins, has become the first European company to secure regulatory approval for cultivated meat, with the Singapore Food Agency granting clearance for its cultivated chicken. It’s a historic moment for Europe’s food-tech sector, but one that’s unfolding thousands of miles away from home.
undefined
Oct 29, 2025 • 4min

Gourmey acquires Vital Meat and forms PARIMA to industrialize of cultivated food

Building a next-generation food company.
undefined
Oct 27, 2025 • 4min

Poolside launches Project Horizon: 2GW of AI compute

Integrating across compute, power, and intelligence.
undefined
Oct 9, 2025 • 7min

The State of AI Report 2025

The State of AI Report is the most widely read and trusted analysis of key developments in AI. Published annually since 2018, the open-access report aims to spark informed conversation about the state of AI and what it means for the future. Produced by AI investor Nathan Benaich and Air Street Capital. State of AI Report 2025 is reviewed by leading AI practioners in industry and research.
undefined
Sep 19, 2025 • 2min

Air Street Capital partners with NVIDIA on a £2B investment to accelerate the UK AI ecosystem

AI is the ultimate force multiplier on technological progress in our digital, data-driven world. Our mission at Air Street Capital has always been to back the most ambitious teams building breakthrough AI products that would have seemed like magic when I started investing over a decade ago. Key to these inflection points is the infrastructure that enables them: NVIDIA computing systems. I have long argued that NVIDIA is the defining company of the AI era, powering breakthroughs in science, industry, and national strategy. This is why I’m excited to share that we are deepening that story together: Air Street Capital is partnering with NVIDIA as part of its new £2B commitment to the UK AI ecosystem.
undefined
Aug 26, 2025 • 4min

Our investment in Delfa to fix clinical trials

Clinical trials are the bottleneck of the pharmaceutical industry. They’re slow, expensive, and often fail, not only because the science frequently doesn’t pan out, but because the ops don’t either. That’s why we’re leading the $3.8M Seed round for Delfa. The team is building an AI-native operating system for clinical trials, starting with patient enrolment, the most broken part of the process.
undefined
Aug 14, 2025 • 3min

Studio Atelico raises $5M to build the AI-first games studio

We’re excited to announce Air Street Capital’s lead investment in Studio Atelico’s $5M Seed round, alongside friends including Chris Ré (Stanford), Thomas Wolf (Hugging Face), and Alex Ratner (Snorkel), to back a team on a mission to redefine the role of generative AI in games.
undefined
Aug 3, 2025 • 36min

Guide to AI: August 2025

Welcome to the latest issue of your guide to AI, an editorialized newsletter covering the key developments in AI policy, research, industry, and start-ups over the last month.
undefined
Jul 31, 2025 • 5min

Profluent’s OpenCRISPR-1 published in Nature magazine

Gene editing has the potential to solve fundamental challenges in agriculture, biotechnology and human health. CRISPR-based gene editors derived from microorganisms, although powerful, often show notable functional tradeoffs when ported into non-native environments, such as human cells1. Artificial-intelligence-enabled design provides a powerful alternative with the potential to bypass evolutionary constraints and generate editors with optimal properties. Here, using large language models2 trained on biological diversity at scale, we demonstrate successful precision editing of the human genome with a programmable gene editor designed with artificial intelligence. To achieve this goal, we curated a dataset of more than 1 million CRISPR operons through systematic mining of 26 terabases of assembled genomes and metagenomes. We demonstrate the capacity of our models by generating 4.8× the number of protein clusters across CRISPR–Cas families found in nature and tailoring single-guide RNA sequences for Cas9-like effector proteins. Several of the generated gene editors show comparable or improved activity and specificity relative to SpCas9, the prototypical gene editing effector, while being 400 mutations away in sequence. Finally, we demonstrate that an artificial-intelligence-generated gene editor, denoted as OpenCRISPR-1, exhibits compatibility with base editing. We release OpenCRISPR-1 to facilitate broad, ethical use across research and commercial applications.
undefined
Jul 29, 2025 • 5min

Defense AI company Delian Alliance Industries raises a $14M Series A

No one is coming to save Europe. We must build new primes here and now.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app